- Home
- INZY vs WNEB Comparison
INZY vs WNEB Comparison
Compare INZY & WNEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- WNEB
- Stock Information
- Founded
- INZY 2015
- WNEB 1853
- Country
- INZY United States
- WNEB United States
- Employees
- INZY N/A
- WNEB N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- WNEB Savings Institutions
- Sector
- INZY Health Care
- WNEB Finance
- Exchange
- INZY Nasdaq
- WNEB Nasdaq
- Market Cap
- INZY 188.2M
- WNEB 191.1M
- IPO Year
- INZY 2020
- WNEB N/A
- Fundamental
- Price
- INZY $1.36
- WNEB $9.35
- Analyst Decision
- INZY Strong Buy
- WNEB Buy
- Analyst Count
- INZY 8
- WNEB 3
- Target Price
- INZY $17.75
- WNEB $9.75
- AVG Volume (30 Days)
- INZY 1.0M
- WNEB 48.1K
- Earning Date
- INZY 03-11-2025
- WNEB 01-28-2025
- Dividend Yield
- INZY N/A
- WNEB 3.00%
- EPS Growth
- INZY N/A
- WNEB N/A
- EPS
- INZY N/A
- WNEB 0.56
- Revenue
- INZY N/A
- WNEB $73,385,000.00
- Revenue This Year
- INZY N/A
- WNEB N/A
- Revenue Next Year
- INZY N/A
- WNEB $10.26
- P/E Ratio
- INZY N/A
- WNEB $16.73
- Revenue Growth
- INZY N/A
- WNEB N/A
- 52 Week Low
- INZY $1.24
- WNEB $6.00
- 52 Week High
- INZY $7.80
- WNEB $10.08
- Technical
- Relative Strength Index (RSI)
- INZY 29.28
- WNEB 58.60
- Support Level
- INZY $1.35
- WNEB $9.25
- Resistance Level
- INZY $1.62
- WNEB $9.47
- Average True Range (ATR)
- INZY 0.13
- WNEB 0.16
- MACD
- INZY 0.04
- WNEB 0.06
- Stochastic Oscillator
- INZY 32.89
- WNEB 76.71
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the Company's revenues, profits, and assets are derived by the Bank from banking products and services.